ResearcherSeoul National UniversityActive in the last 2 years

Youngro Byun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3863-2236; OpenAlex author ID A5032796168. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 2

Macropinocytosis-targeted peptide-docetaxel conjugate for bystander pancreatic cancer treatment. Last author DOI 10.1016/j.jconrel.2024.10.070 ↗
Anticancer Effect of Heparin-Taurocholate Conjugate on Orthotopically Induced Exocrine and Endocrine Pancreatic Cancer. Co-author DOI 10.3390/cancers13225775 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Kwangmeyung Kim · 1 shared paper, 2024 · strength 0.21
- Paper Macropinocytosis-targeted peptide-docetaxel conjugate for bystander pancreatic cancer treatment. DOI 10.1016/j.jconrel.2024.10.070 ↗
Young Seok Cho · 1 shared paper, 2024 · strength 0.21
- Paper Macropinocytosis-targeted peptide-docetaxel conjugate for bystander pancreatic cancer treatment. DOI 10.1016/j.jconrel.2024.10.070 ↗
Hae Hyun Hwang · 1 shared paper, 2021 · strength 0.15
- Paper Anticancer Effect of Heparin-Taurocholate Conjugate on Orthotopically Induced Exocrine and Endocrine Pancreatic Cancer. DOI 10.3390/cancers13225775 ↗
Dong Yun Lee · 1 shared paper, 2021 · strength 0.15
- Paper Anticancer Effect of Heparin-Taurocholate Conjugate on Orthotopically Induced Exocrine and Endocrine Pancreatic Cancer. DOI 10.3390/cancers13225775 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.